These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 20738033

  • 21. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
    Drab SR.
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
    [Abstract] [Full Text] [Related]

  • 22. Incretins and their role in the management of diabetes.
    Frias JP, Edelman SV.
    Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B.
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
    Davies MJ, Kela R, Khunti K.
    Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.
    Voukali M, Kastrinelli I, Stragalinou S, Tasiopoulou D, Paraskevopoulou P, Katsilambros N, Kokkinos A, Tentolouris N, Ioannidis I.
    J Diabetes Res; 2014 Apr; 2014():304032. PubMed ID: 25165723
    [Abstract] [Full Text] [Related]

  • 33. Liraglutide in type 2 diabetes mellitus.
    Baruah MP, Chaudhury T, Sethi BK, Dharmalingam M.
    J Indian Med Assoc; 2012 May; 110(5):335-8. PubMed ID: 23360033
    [Abstract] [Full Text] [Related]

  • 34. Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
    Haraguchi A, Fujishima K, Ando T, Mori F, Imaizumi M, Abiru N, Yamasaki H, Matsumoto K, Takamura N, Kawakami A.
    Minerva Endocrinol; 2014 Dec; 39(4):289-97. PubMed ID: 25371055
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Liraglutide].
    Takahashi T, Odawara M.
    Nihon Rinsho; 2011 May; 69(5):883-9. PubMed ID: 21595276
    [Abstract] [Full Text] [Related]

  • 38. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY, Ryder RE, Cull ML, Walton C, ABCD Nationwide Exenatide and Liraglutide Audit Contributors.
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.